A-SEEDS

a-seeds.co.jp

a-seeds.co.jp • Series A 2025 • 51-200 employees • Startup

Series A 2025 • 51-200 employees • Startup

Cell & Gene Therapy

Claim pageClaim

Overview

News

Salaries

Products

People

Growth

Offices

Financials

Funding and backers

Total raised

$16.2M

1 round on record

Latest round

$16.2M

Series A · Jul 2025 · 15 mo ago

Team

51-200

employees, estimated range

Backers

NVCC

The money's age

Due for its next round

15 months since the last round · not hiring

Momentum

0/100

no fresh signals

Last sign of life

this month

a posting or a news item

The story so fareach stage dated by its source: the company's releases, the press, registers, filings

Jul 7, 2025 Raised a round Series A $16.2M

Funding rounds

Round	Date	Amount	Investors	Source
Series A	Jul 2025	$16.2M	—	a-seeds.co.jp

Backed byfrom the funds' portfolios and accelerator catalogs

NVCC fund

Investors in similar startupsfunds that back the companies most like this one

Techstars

backs Restore Vision const embeddedUl = document

Insight Partners

backs Profluent

backs Sonoma Biotherapeutics

8VC

backs Sonoma Biotherapeutics

ARCH Venture Partners

backs Jaguar Gene Therapy

Salesforce Ventures

backs Profluent

Similar startupsby what they do, their industry and backers

Restore Vision const embeddedUl = document

Restore Vision is a startup based in Japan aiming to develop a visual restoration gene therapy.

Ishin Co., Ltd.

About Us 私たちが大切にしていること代表取締役社長西中大史代表取締役会長明石智義代表メッセージ当社は社是に「事業家創発」、理念に「世界的視野を持った事業家たちが差別化された事業を通じて社会の進化に貢献する」を掲げております。…

GenEditBio

计时中 Home About Pipeline Science Overview PDV LNP News Careers Leadership Zongli ZHENG Co-Founder, Chairman MORE ▶ Tian ZHU Co-Founder，CEO…

QimmuneVenture round $25k · this month • Founded 2025

Q-Immune provides cutting-edge real-time protein network analysis for CAR-T cells, enabling accurate efficacy prediction, optimized CAR-T…

ProfluentVenture round $106M · 10 mo ago • Founded 2022 • 51-200 employees • 16 roles

Profluent is a company founded in 2022 that trains large language models on protein sequences to design new functional proteins. It…

Addition TherapeuticsVenture round $100M · 10 mo ago • Founded 2021 • 3 roles

We're on a mission to fulfill the promise of genetic medicine for all patients. At Addition, we are advancing a pipeline of therapeutics to…

Overview

Company A-SEEDSについて Home A-SEEDSについて代表メッセージ当社は、遺伝子改変免疫細胞療法をいち早く患者さんのもとへと届けたい、という信念のもと、2020年に信州大学発ベンチャーとして誕生しました。小児科医であるわたしたちは、たくさんの小児・若年成人のがん患者さんの治療に取り組みながら、たくましく毎日をすごしているこどもたちを見て、小児がん治療医としての使命をいつも考えていました。「がんに対する既存の最新の治療を実践することで、こどもたちの未来を考えながら、後遺症のない生存を目指す（Intact survival for the future…